A-shares closed · 港股休市 Quotes 行情 · 28 Sep 16:29 CST
28 Sep 2026 · 20:04 CST Terminal Access 终端入口 →
600771.SH上海证券交易所 · 主板 Main

Guangyuyuan 广誉远

Traditional Chinese Medicine 中药Ⅱ
¥14.04+¥0.39 · +2.86%Delayed 行情延迟 · 28 Sep 2026 · 16:14 CST · CNY
Open 开盘
¥13.69
High 最高
¥14.29
Low 最低
¥13.59
Prev Close 昨收
¥13.65
Volume 成交量
1,366.3万股
Turnover 成交额
¥1.91亿
Mkt Cap 总市值
¥69亿
P/E 市盈率
97.0×
Recent Activity 近期动态All Filings 全部公告 →

3 significant filings since 31 May 2026: 1 on litigation, 1 on government subsidy and 1 on buyback. The latest, on 15 Jul 2026: 广誉远中药股份有限公司关于重大诉讼的进展公告. 1 unverified report logged, the latest on 11 Jun 2026.
自 31 May 2026 起有 3 份重大公告:litigation 1 份、government subsidy 1 份、buyback 1 份。最新一份(15 Jul 2026):广誉远中药股份有限公司关于重大诉讼的进展公告。记录了 1 条未经核实的报道,最新一条见于 11 Jun 2026。

Price History 价格走势

5 sessions 个交易日, 21 Sep to 28 Sep 2026 · Live one-minute prices 实时分钟价格 · High 最高 ¥14.26 · Low 最低 ¥13.59 · +2.86% on the previous close of ¥13.65 较昨收
13.6013.7013.8013.9014.0014.1014.20
Volume 成交量
9,984
21 Sep22 Sep23 Sep24 Sep28 Sep
Last Twelve Months 近十二个月

No broker reports from the last twelve months are held for this company. Brokers covered 1,185 of the 2,361 SSE listings (50%) over the same period. 近十二个月无本公司研报;同期券商覆盖了 2,361 只 SSE 证券中的 1,185 只(50%)。

Rating Changes 评级变动
2 up · 0 down in all reports held 全部研报中上调 2 次,下调 0 次
Date 日期Broker 券商Analyst 分析师From 原评级To 新评级
15 May 2018东兴证券张金洋,缪牧一Outperform 增持▲Buy 买入
24 Apr 2018联讯证券李志新Outperform 增持▲Buy 买入

Each broker's rating is compared with its previous report. 每家券商的评级与其上一份研报比较。

Coverage by Quarter 覆盖变化
0 23Q4
0 24Q1
0 24Q2
0 24Q3
0 24Q4
0 25Q1
1 25Q2
0 25Q3
0 25Q4
0 26Q1
0 26Q2
0 26Q3

Each bar counts the brokers publishing on this company in a quarter. The latest quarter is not yet complete. 每根柱为该季度发布本公司研报的券商数,最近一个季度尚未结束。